Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial

Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial

Abstract Background Mexico has one of the highest prevalence rates of obesity worldwide. New pharmacological strategies that focus on people with class III obesity are required. Metformin and dapagliflozin are two drugs approved for the treatment of diabetes. Beyond its effects on glucose, metformin...

Full description

Bibliographic Details
Main Authors: Aldo Ferreira-Hermosillo, Mario Antonio Molina-Ayala, Diana Molina-Guerrero, Ana Pamela Garrido-Mendoza, Claudia Ramírez-Rentería, Victoria Mendoza-Zubieta, Etual Espinosa, Moisés Mercado
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Trials
Subjects:
Metformin
Sodium-glucose transporter 2 inhibitors
Prediabetes
Obesity
Morbid
Type 2 Diabetes Mellitus
Online Access:https://doi.org/10.1186/s13063-020-4121-x

Internet

https://doi.org/10.1186/s13063-020-4121-x

Similar Items